BeiGene Blocks US Rival To Brukinsa Blockbuster Until 2037
MSN Agrees Settlement Allowing Zanubrutinib Launch In 13 Years
MSN Laboratories has struck a patent-litigation settlement deal with BeiGene that will allow it to launch its zanubrutinib generic rival to Brukinsa in the US from 2037.
